Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer

Cancer Epidemiology

Volumn 37, Issue 4, 2013, Pages 505-511

  Troy, Jesse D ^a,c   Weissfeld, Joel L ^a,c   Diergaarde, Brenda ^a,c   Youk, Ada O ^a   Buch, Shama C ^b   Romkes, Marjorie ^b,c   Grandis, Jennifer R ^b,c  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

GSTP1; Head and neck neoplasms; NAT2; Polymorphism single nucelotide; SNP

Indexed keywords

FLUOROURACIL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; DISEASE SPECIFIC SURVIVAL; DNA POLYMORPHISM; FEMALE; GENE ACTIVITY; GENETIC ASSOCIATION; GLUTATHIONE TRANSFERASE P1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; N ACTEYLTRANSFERASE 2 GENE; OROPHARYNX CANCER; PHENOTYPE; PRIORITY JOURNAL; TUMOR GENE; TUMOR LOCALIZATION;

AGED; ALCOHOL DRINKING; ARYLAMINE N-ACETYLTRANSFERASE; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; GLUTATHIONE S-TRANSFERASE PI; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; SMOKING; SURVIVAL RATE;

EID: 84878938134     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.02.009     Document Type: Article

References (39)

1. Mehanna H., Paleri V., West C.M., Nutting C. Head and neck cancer. Part 1: epidemiology, presentation, and prevention. BMJ 2010, 341:c4684.
2. Hashibe M., Brennan P., Benhamou S., Castellsague X., Chen C., Curado M.P., et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007, 99(10):777-789.
3. Hashibe M., Brennan P., Chuang S.C., Boccia S., Castellsague X., Chen C., et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009, 18(2):541-550.
4. Nebert D.W., Dalton T.P. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006, 6(12):947-960.
5. Zhang Z.J., Hao K., Shi R., Zhao G., Jiang G.X., Song Y., et al. Glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null polymorphisms, smoking, and their interaction in oral cancer: a HuGE review and meta-analysis. Am J Epidemiol 2011, 173(8):847-857.
6. Hashibe M., Brennan P., Strange R.C., Bhisey R., Cascorbi I., Lazarus P., et al. Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2003, 12(12):1509-1517.
7. Lacko M., Oude Ophuis M.B., Peters W.H., Manni J.J. Genetic polymorphisms of smoking-related carcinogen detoxifying enzymes and head and neck cancer susceptibility. Anticancer Res 2009, 29(2):753-761.
8. Ekhart C., Rodenhuis S., Smits P.H., Beijnen J.H., Huitema A.D. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev 2009, 35(1):18-31.
9. Walker K., Ginsberg G., Hattis D., Johns D.O., Guyton K.Z., Sonawane B. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health B: Crit Rev 2009, 12(5/6):440-472.
10. Wang S., Chanock S., Tang D., Li Z., Jedrychowski W., Perera F.P. Assessment of interactions between PAH exposure and genetic polymorphisms on PAH-DNA adducts in African American, Dominican, and Caucasian mothers and newborns. Cancer Epidemiol Biomarkers Prev 2008, 17(2):405-413.
11. Poveda-Roda R., Bagan J.V., Jimenez-Soriano Y., Margaix-Munoz M., Sarrion-Perez G. Changes in smoking habit among patients with a history of oral squamous cell carcinoma (OSCC). Med Oral Patol Oral Cir Bucal 2010, 15(5):e721-e726.
12. Jensen K., Jensen A.B., Grau C. Smoking has a negative impact upon health related quality of life after treatment for head and neck cancer. Oral Oncol 2007, 43(2):187-192.
13. Ostroff J.S., Jacobsen P.B., Moadel A.B., Spiro R.H., Shah J.P., Strong E.W., et al. Prevalence and predictors of continued tobacco use after treatment of patients with head and neck cancer. Cancer 1995, 75(2):569-576.
14. Mayne S.T., Cartmel B., Kirsh V., Goodwin W.J. Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx. Cancer Epidemiol Biomarkers Prev 2009, 18(12):3368-3374.
15. Pulte D., Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010, 15(9):994-1001.
16. Fung C., Grandis J.R. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs 2010, 15(3):355-373.
17. Olivieri E.H., da Silva S.D., Mendonça F.F., Urata Y.N., Vidal D.O., Faria M.A., et al. CYP1A2*1C, CYP2E1*5B, and GSTM1 polymorphisms are predictors of risk and poor outcome in head and neck squamous cell carcinoma patients. Oral Oncol 2009, 45(9):e73-e79.
18. Geisler S.A., Olshan A.F., Cai J., Weissler M., Smith J., Bell D. Glutathione S-transferase polymorphisms and survival from head and neck cancer. Head Neck 2005, 27(3):232-242.
19. Minard C.G., Spitz M.R., Wu X., Hong W.K., Etzel C.J. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer 2006, 106(12):2636-2644.
20. Buch S.C., Nazar-Stewart V., Weissfeld J.L., Romkes M. Case-control study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes. Head Neck 2008, 30(9):1139-1147.
21. Khedhaier A., Hassen E., Bouaouina N., Gabbouj S., Ahmed S.B., Chouchane L. Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC Cancer 2008, 8:109.
22. Ambrosone C.B., Ahn J., Singh K.K., Rezaishiraz H., Furberg H., Sweeney C., et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 2005, 65(3):1105-1111.
23. Osian G., Procopciuc L., Vlad L., Iancu C., Cristea P.G., Mocan T., et al. NAT2 polymorphisms and sporadic colorectal cancer survival. J Gastrointestinal Liver Dis 2010, 19(4):361-368.
24. Al-Moundhri M.S., Al-Kindi M., Al-Nabhani M., Al-Bahrani B., Burney I.A., Al-Madhani A., et al. NAT2 polymorphism in Omani gastric cancer patients-risk predisposition and clinicopathological associations. World J Gastroenterol 2007, 13(19):2697-2702.
25. Kiyohara C., Yoshimasu K., Takayama K., Nakanishi Y. NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med 2005, 7(7):463-478.
26. Crabb D.W., Liangpunsakul S. Acetaldehyde generating enzyme systems: roles of alcohol dehydrogenase, CYP2E1 and catalase, and speculations on the role of other enzymes and processes. Novartis Found Symp 2007, 285:4-16.
27. Ali-Osman F., Akande O., Antoun G., Mao J.X., Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants, evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997, 272(15):10004-10012.
28. Bolt H.M., Thier R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr Drug Metab 2006, 7(August (6)):613-628.
29. Consensus Human Arylamine N-Acetyltransferase Gene Nomenclature - University of Louisville [cited 2011 May 2]; Available from: http://louisville.edu/medschool/pharmacology/consensus-human-arylamine-n-acetyltransferase-gene-nomenclature/.
30. Ginsberg G., Smolenski S., Hattis D., Guyton K.Z., Johns D.O., Sonawane B. Genetic polymorphism in glutathione transferases (GST): population distribution of GSTM1, T1, and P1 conjugating activity. J Toxicol Environ Health B: Crit Rev 2009, 12(5/6):389-439.
31. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xiao G.H., et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000, 9(1):29-42.
32. Ashton L.J., Murray J.E., Haber M., Marshall G.M., Ashley D.M., Norris M.D. Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma. Pharmacogenet Genomics 2007, 17(9):709-717.
33. Han X., Zheng T., Foss F.M., Lan Q., Holford T.R., Rothman N., et al. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. Am J Hematol 2010, 85(1):51-56.
34. Muller P., Asher N., Heled M., Cohen S.B., Risch A., Rund D. Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leuk Res 2008, 32(6):919-929.
35. Krajinovic M., Labuda D., Mathonnet G., Labuda M., Moghrabi A., Champagne J., et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 2002, 8(3):802-810.
36. Butcher N.J., Minchin R.F. Arylamine N-acetyltransferase 1: a novel drug target in cancer development. Pharmacol Rev 2012, 64(1):147-165.
37. Masood N., Malik F.A., Kayani M.A. Expression of xenobiotic metabolizing genes in head and neck cancer tissues. Asian Pac J Cancer Prev 2011, 12(2):377-382.
38. Ruwali M., Pant M.C., Shah P.P., Mishra B.N., Parmar D. Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome. Mutat Res 2009, 669(1-2):36-41.
39. Mitrunen K., Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 2003, 544(1):9-41.